JPRN-UMIN000043973尚未招募2 期
2-HLA-haplotype-mismatched hematopietic stem cell transplantation - 2-HLA-haplotype-mismatched HSCT
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) serum Cre >2.0 mg/dl 2) serum T-Bil >2.0 mg/dl 3) selum AST and/or ALT >200 U/L 4) EF <45% 5) SpO2 <95% (room air) 6) PS (ECOG score) 3-4
研究者
相似试验
招募中
不适用
HLA 2-3 antigen-mismatched stem cell transplantation for refracotry hematologic malignanciesJPRN-UMIN000011985Jikei University School of Medicine25
已完成
不适用
HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic diseasesAcute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Secondary acute myelogenous leukemia Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)JPRN-UMIN000002069Hematology, Osaka City University, Graduate School of Medicine17
已完成
2 期
HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic malignancies (OCU13-3)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)JPRN-UMIN000011293Osaka City University35
已完成
2 期
HLA-haploidentical allogeneic stem cell transplantation for Adult T-cell leukemia/lymphoma (ATL/L) and refractory aggressive lymphomaAdult T-cell leukemia/lymphoma (acute type and lymphoma type) Malignant lymphoma (aggressive hodgkin and non-hodgkin lymphoma)JPRN-UMIN000002606Hematology, Osaka City University, Graduate School of Medicine17
已完成
1 期
Haploidentical hematopoietic stem cell transplantation in combination with posttransplant cyclophosphamide and ATG-thymoglobulin Phase I studyhematological malignancyJPRN-UMIN000009374ational Cancer Center Hospital15